We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0SZI market cap is 0. The company's latest EPS is USD -10.0821 and P/E is -3.40.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 36.14M | 3.94M | 882k | 0 | 0 |
| Operating Income | -77.1M | -122.81M | -55.99M | -39.84M | -45.08M |
| Net Income | -71.45M | -111.27M | -45.64M | -42.35M | -44.6M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 49.14M | 102.3M | 107.73M | 66.31M | 28.27M |
| Total Liabilities | 42.98M | 57.02M | 38.62M | 33.32M | 35.18M |
| Total Equity | 6.16M | 45.28M | 69.11M | 32.99M | -6.91M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -45.72M | -99.69M | -48.18M | -37.54M | -36.1M |
| Investing | -2.74M | -485k | -73.42M | 30.07M | 35.64M |
| Financing | 38.47M | 154.88M | 60.82M | -534k | -2.82M |
| Market Cap | 0 |
| Price to Earnings Ratio | -3.40 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 11.04 |
| Price to Book Ratio | -21.95 |
| Dividend Yield | - |
| Shares Outstanding | 4.42M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Corbus Pharmaceuticals Holdings Inc |
| Address |
850 new burton road dover, delaware 19904 |
| Website | https://www.corbuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
